CNPV
May 8, 2026
Partner Therapeutics receives FDA approval for Bizengri (zenocutuzumab-zbco) under the Commissioner’s National Priority Voucher pilot program
The U.S. Food and Drug Administration today approved Bizengri (zenocutuzumab-zbco) for NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.
Bizengri is the first drug approved for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This approval was awarded to Partner Therapeutics, Inc and marks the seventh approval under the Commissioner’s National Priority Voucher pilot program.
